J&J vets burst into biotech with $165M Third Arc series A

A clutch of Johnson & Johnson veterans have burst onto the biotech scene, launching Third Arc Bio with $165 million to take multifunctional antibodies into the clinic in solid tumors and autoimmune diseases.